Distinct pattern of hypometabolism and atrophy in preclinical and predementia Alzheimer's disease

Neurobiology of Aging

Volumn 35, Issue 9, 2014, Pages 1973-1981

  Kljajevic, Vanja ^a   Grothe, Michel Jan ^a   Ewers, Michael ^b   Teipel, Stefan ^a,c  

^a GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Alzheimer's disease; Amyloid; Imaging biomarkers; Mild cognitive impairment

Indexed keywords

AMYLOID BETA PROTEIN; FLUORODEOXYGLUCOSE F 18; AMYLOID PROTEIN; FLUORINE; RADIOPHARMACEUTICAL AGENT;

AGE; AGED; ALZHEIMER DISEASE; ANALYSIS OF COVARIANCE; APOE EPSILON4 GENE; AREA UNDER THE CURVE; ARTICLE; BRAIN ATROPHY; BRAIN CORTEX; BRAIN SIZE; CELL LOSS; COGNITION; CONTROLLED STUDY; CORTICAL THICKNESS (BRAIN); DEMENTIA; DISEASE CLASSIFICATION; EARLY MILD COGNITIVE IMPAIRMENT; EDUCATION; FEMALE; GENDER; GENE; GRAY MATTER; GRAY MATTER HYPOMETABOLISM; HUMAN; LATE MILD COGNITIVE IMPAIRMENT; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NERVE CELL; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; ONSET AGE; POSITRON EMISSION TOMOGRAPHY; PREDEMENTIA; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SYNAPSE; VOXEL BASED MORPHOMETRY; ATROPHY; DIAGNOSTIC USE; METABOLISM; MIDDLE AGED; PATHOLOGY; SCINTISCANNING; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOIDOGENIC PROTEINS; ATROPHY; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; GRAY MATTER; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SYNAPSES;

EID: 84902116283     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2014.04.006     Document Type: Article

References (45)

1. Albert M.S., DeKosky S.T., Dickson D., Dubois B., Feldman H.H., Fox N.C., Gamst A., Holtzman D.M., Jagust W.J., Petersen R.C., Snyder P.J., Carrillo M.C., Thies B., Phelps C.H. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:270-279.
2. Ashburner J. Afast diffeomorphic image registration algorithm. Neuroimage 2007, 38:95-113.
3. Barnes J., Ridgway G.R., Bartlett J., Henley S.M., Lehmann M., Hobbs N., Clarkson M.J., MacManus D.G., Ourselin S., Fox N.C. Head size, age and gender adjustment in MRI studies: a necessary nuisance?. Neuroimage 2010, 53:1244-1255.
4. Bateman R.J., Xiong C., Benzinger T.L., Fagan A.M., Goate A., Fox N.C., Marcus D.S., Cairns N.J., Xie X., Blazey T.M., Holtzman D.M., Santacruz A., Buckles V., Oliver A., Moulder K., Aisen P.S., Ghetti B., Klunk W.E., McDade E., Martins R.N., Masters C.L., Mayeux R., Ringman J.M., Rossor M.N., Schofield P.R., Sperling R.A., Salloway S., Morris J.C. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. New Engl. J. Med. 2012, 367:795-804.
5. Benzinger T.L., Blazey T., Jack C.R., Koeppe R.A., Su Y., Xiong C., Raichle M.E., Snyder A.Z., Ances B.M., Bateman R.J., Cairns N.J., Fagan A.M., Goate A., Marcus D.S., Aisen P.S., Christensen J.J., Ercole L., Hornbeck R.C., Farrar A.M., Aldea P., Jasielec M.S., Owen C.J., Xie X., Mayeux R., Brickman A., McDade E., Klunk W., Mathis C.A., Ringman J., Thompson P.M., Ghetti B., Saykin A.J., Sperling R.A., Johnson K.A., Salloway S., Correia S., Schofield P.R., Masters C.L., Rowe C., Villemagne V.L., Martins R., Ourselin S., Rossor M.N., Fox N.C., Cash D.M., Weiner M.W., Holtzman D.M., Buckles V.D., Moulder K., Morris J.C. Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A 2013, 110:E4502-E4509.
6. Buchhave P., Minthon L., Zetterberg H., Wallin A.K., Blennow K., Hansson O. Cerebrospinal fluid levels of beta-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch. Gen. Psychiatry 2012, 69:98-106.
7. Castellani R.J., Smith M.A. Compounding artefacts with uncertainty, and an amyloid cascade hypothesis that is 'too big to fail'. J.Pathol. 2011, 224:147-152.
8. Chetelat G., Desgranges B., Landeau B., Mezenge F., Poline J.B., Sayette V., Viader F., Eustache F., Baron J.-C. Direct voxel-based comparison between grey matter hypometabolism and atrophy in Alzheimer's disease. Brain 2008, 131:60-71.
9. Cohen A.D., Price J.C., Weissfeld L.A., James J., Rosario B.L., Bi W., Nebes R.D., Saxton J.A., Snitz B.E., Aizenstein H.A., Wolk D.A., Dekosky S.T., Mathis C.A., Klunk W.E. Basal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: an example of brain reserve. J.Neurosci. 2009, 29:14770-14778.
10. Dale A.M., Fischl B., Sereno M.I. Cortical surface-based analysis. I. Segmentation and surface reconstruction. Neuroimage 1999, 9:179-194.
11. Desikan R.S., Segonne F., Fischl B., Quinn B.T., Dickerson B.C., Blacker D., Buckner R.L., Dale A.M., Maguire R.P., Hyman B.T., Albert M.S., Killiany R.J. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage 2006, 31:968-980.
12. Dickerson B.C., Bakkour A., Salat D.H., Feczko E., Pacheco J., Greve D.N., Grodstein F., Wright C.I., Blacker D., Rosas H.D., Sperling R.A., Atri A., Growdon J.H., Hyman B.T., Morris J.C., Fischl B., Buckner R.L. The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb. Cortex 2009, 19:497-510.
13. Drzezga A., Becker J.A., Van Dijk K.R., Sreenivasan A., Talukdar T., Sullivan C., Schultz A.P., Sepulcre J., Putcha D., Greve D., Johnson K.A., Sperling R.A. Neuronal dysfunction and disconnection of cortical hubs in non-demented subjects with elevated amyloid burden. Brain 2011, 134:1635-1646.
14. Dubois B., Feldman H.H., Jacova C., Cummings J.L., Dekosky S.T., Barberger-Gateau P., Delacourte A., Frisoni G., Fox N.C., Galasko D., Gauthier S., Hampel H., Jicha G.A., Meguro K., O'Brien J., Pasquier F., Robert P., Rossor M., Salloway S., Sarazin M., de Souza L.C., Stern Y., Visser P.J., Scheltens P. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 2010, 9:1118-1127.
15. Dubois B., Feldman H.H., Jacova C., Dekosky S.T., Barberger-Gateau P., Cummings J., Delacourte A., Galasko D., Gauthier S., Jicha G., Meguro K., O'brien J., Pasquier F., Robert P., Rossor M., Salloway S., Stern Y., Visser P.J., Scheltens P. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007, 6:734-746.
16. Ewers M., Brendel M., Rizk-Jackson A., Rominger A., Bartenstein P., Schuff N., Weiner M.W. Reduced FDG-PET brain metabolism and executive function predict clinical progression in elderly healthy subjects. Neuroimage Clin. 2013, 4:45-52.
17. Fischl B., Sereno M.I., Dale A.M. Cortical surface-based analysis. II: inflation, flattening, and a surface-based coordinate system. Neuroimage 1999, 9:195-207.
18. Glenner G.G., Wong C.W. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 1984, 120:885-890.
19. Grothe M., Heinsen H., Teipel S. Longitudinal measures of cholinergic forebrain atrophy in the transition from healthy aging to Alzheimer's disease. Neurobiol. Aging 2013, 34:1210-1220.
20. Hardy J., Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol. Sci. 1991, 12:383-388.
21. Hardy J.A., Higgins G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992, 256:184-185.
22. Jack C.R., Knopman D.S., Jagust W.J., Petersen R.C., Weiner M.W., Aisen P.S., Shaw L.M., Vemuri P., Wiste H.J., Weigand S.D., Lesnick T.G., Pankratz V.S., Donohue M.C., Trojanowski J.Q. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013, 12:207-216.
23. Jack C.R., Knopman D.S., Jagust W.J., Shaw L.M., Aisen P.S., Weiner M.W., Petersen R.C., Trojanowski J.Q. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010, 9:119-128.
24. Jack C.R., Knopman D.S., Weigand S.D., Wiste H.J., Vemuri P., Lowe V., Kantarci K., Gunter J.L., Senjem M.L., Ivnik R.J., Roberts R.O., Rocca W.A., Boeve B.F., Petersen R.C. An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann. Neurol. 2012, 71:765-775.
25. Jagust W.J., Landau S.M. Apolipoprotein E, not fibrillar beta-amyloid, reduces cerebral glucose metabolism in normal aging. J.Neurosci. 2012, 32:18227-18233.
26. Jagust W.J., Landau S.M., Shaw L.M., Trojanowski J.Q., Koeppe R.A., Reiman E.M., Foster N.L., Petersen R.C., Weiner M.W., Price J.C., Mathis C.A. Relationships between biomarkers in aging and dementia. Neurology 2009, 73:1193-1199.
27. Karran E., Mercken M., De Strooper B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat. Rev. 2011, 10:698-712.
28. Khachaturian A.S., Mielke M.M., Khachaturian Z.S. Biomarker development: a population-level perspective. Alzheimers Dement. 2012, 8:247-249.
29. Lee H.G., Casadesus G., Zhu X., Takeda A., Perry G., Smith M.A. Challenging the amyloid cascade hypothesis: senile plaques and amyloid-beta as protective adaptations to Alzheimer disease. Ann. N.Y. Acad. Sci. 2004, 1019:1-4.
30. Metz C.E., Herman B.A., Roe C.A. Statistical comparison of two ROC-curve estimates obtained from partially-paired datasets. Med. Decis. Making 1998, 18:110-121.
31. Mormino E.C., Kluth J.T., Madison C.M., Rabinovici G.D., Baker S.L., Miller B.L., Koeppe R.A., Mathis C.A., Weiner M.W., Jagust W.J. Episodic memory loss is related to hippocampal-mediated -amyloid deposition in elderly subjects. Brain 2009, 132:1310-1323.
32. Morris J.C., Roe C.M., Xiong C., Fagan A.M., Goate A.M., Holtzman D.M., Mintun M.A. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann. Neurol. 2010, 67:122-131.
33. Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur. J. Nucl. Med. Mol. Imaging 2005, 32:486-510.
34. Mosconi L., Rinne J.O., Tsui W.H., Berti V., Li Y., Wang H., Murray J., Scheinin N., Någren K., Williams S., Glodzik L., De Santi S., Vallabhajosula S., de Leon M.J. Increased fibrillar amyloid-{beta} burden in normal individuals with a family history of late-onset Alzheimer's. Proc. Natl. Acad. Sci. U.S.A 2010, 107:5949-5954.
35. Mosconi L., Rinne J.O., Tsui W.H., Murray J., Li Y., Glodzik L., McHugh P., Williams S., Cummings M., Pirraglia E., Goldsmith S.J., Vallabhajosula S., Scheinin N., Viljanen T., Någren K., de Leon M.J. Amyloid and metabolic positron emission tomography imaging of cognitively normal adults with Alzheimer's parents. Neurobiol. Aging 2013, 34:22-34.
36. Mosconi L., Sorbi S., de Leon M.J., Li Y., Nacmias B., Myoung P.S., Tsui W., Ginestroni A., Bessi V., Fayyazz M., Caffarra P., Pupi A. Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease. J.Nucl. Med. 2006, 47:1778-1786.
37. Nordberg A., Carter S.F., Rinne J., Drzezga A., Brooks D.J., Vandenberghe R., Perani D., Forsberg A., Långström B., Scheinin N., Karrasch M., Någren K., Grimmer T., Miederer I., Edison P., Okello A., Van Laere K., Nelissen N., Vandenbulcke M., Garibotto V., Almkvist O., Kalbe E., Hinz R., Herholz K. AEuropean multicentre PET study of fibrillar amyloid in Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 2013, 40:104-114.
38. O'Brien J.L., O'Keefe K.M., LaViolette P.S., DeLuca A.N., Blacker D., Dickerson B.C., Sperling R.A. Longitudinal fMRI in elderly reveals loss of hippocampal activation with clinical decline. Neurology 2010, 74:1969-1976.
39. Ossenkoppele R., van Berckel B.N., Prins N.D. Amyloid imaging in prodromal Alzheimer's disease. Alzheimers Res. Ther. 2011, 3:26.
40. Pimplikar S.W. Reassessing the amyloid cascade hypothesis of Alzheimer's disease. Int. J. Biochem. Cell Biol 2009, 41:1261-1268.
41. Protas H.D., Chen K., Langbaum J.B., Fleisher A.S., Alexander G.E., Lee W., Bandy D., de Leon M.J., Mosconi L., Buckley S., Truran-Sacrey D., Schuff N., Weiner M.W., Caselli R.J., Reiman E.M. Posterior cingulate glucose metabolism, hippocampal glucose metabolism, and hippocampal volume in cognitively normal, late-middle-aged persons at 3 levels of genetic risk for Alzheimer disease. JAMA Neurol. 2013, 70:320-325.
42. Reiman E.M., Caselli R.J., Chen K., Alexander G.E., Bandy D., Frost J. Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: a foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A 2001, 98:3334-3339.
43. Reiman E.M., Chen K., Liu X., Bandy D., Yu M., Lee W., Ayutyanont N., Keppler J., Reeder S.A., Langbaum J.B., Alexander G.E., Klunk W.E., Mathis C.A., Price J.C., Aizenstein H.J., DeKosky S.T., Caselli R.J. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A 2009, 106:6820-6825.
44. Sperling R.A., Aisen P.S., Beckett L.A., Bennett D.A., Craft S., Fagan A.M., Iwatsubo T., Jack C.R., Kaye J., Montine T.J., Park D.C., Reiman E.M., Rowe C.C., Siemers E., Stern Y., Yaffe K., Carrillo M.C., Thies B., Morrison-Bogorad M., Wagster M.V., Phelps C.H. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:280-292.
45. Villemagne V.L., Burnham S., Bourgeat P., Brown B., Ellis K.A., Salvado O., Szoeke C., Macaulay S.L., Martins R., Maruff P., Ames D., Rowe C.C., Masters C.L. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neeurol. 2013, 12:357-367.